News & Updates

Patients with inflammatory bowel disease (IBD) can switch from intravenous to subcutaneous vedolizumab treatment in the maintenance setting, with the clinical and biochemical disease activity remaining stable after the change, as shown in a study. However, some patients switch back to intravenous treatment due to adverse events or fear of needles.

Oxycodone delivery via intravenous patient-controlled analgesia (IVPCA) allows women to self-administer analgesics when experiencing pain during medical abortion, helping reduce pain to mild or tolerable levels, according to a study.

New drug applications approved by US FDA as of 16 - 31 July 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Adding pembrolizumab to chemotherapy in the first-line setting significantly prolongs overall survival (OS) in patients with triple-negative breast cancer (TNBC) whose tumours expressed programmed death-ligand 1 (PD-L1) with a CPS* of ≥10, compared with chemotherapy alone, according to the KEYNOTE-355** trial.

Polypharmacy frequently occurs in most patients with advanced cancer at end of life, reports a recent study. However, most medications used are usually for supportive care.